News Details

expanding the realm of possible...

stock datapress releasescorporate eventsdownloads
Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystonias

Geneva, Switzerland, 22 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that the European Patent Office granted Addex a broad composition of matter patent (European patent, EP 1 765 795) covering dipraglurant and other mGlu5 negative allosteric modulators (NAM). Dipraglurant is currently in development for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients as well as rare forms of dystonia.  
“The granting of this patent continues to broaden the patent estate around our lead program,” said Bharatt Chowrira, Ph.D., CEO at Addex.  “Specifically, composition of matter patents have now been granted for dipraglurant in all the major markets – the United States, Europe and Japan.   Our intellectual property estate continues to yield key patents protecting novel oral small molecules discovered utilizing our industry leading allosteric modulation technology platform. This new patent significantly enhances the value of our dipraglurant franchise and we look forward to advancing dipraglurant into Phase 2 for the treatment of certain rare dystonias in the coming months.”
About Dipraglurant
Dipraglurant is an oral, small molecule allosteric modulator that inhibits selectively the metabotropic glutamate receptor 5 (mGlu5), a Class C G-Protein Coupled Receptor (GPCR), with potential to be used in combination with levodopa or dopamine agonists or as a standalone treatment for Parkinson’s disease levodopa-induced dyskinesia (PD-LID), motor and non-motor symptoms of Parkinson’s disease and other movement disorders. Data from a recent Phase 2a show that dipraglurant met the primary objective of the study by exhibiting a good safety and tolerability profile. Dipraglurant also demonstrated a statistically significant reduction in LID severity with both 50 and 100 mg doses. Dipraglurant appears to reduce dystonia severity in addition to chorea, the two major LID components. In a double-blind, placebo-controlled study conducted in the US and Europe, the primary objective was to demonstrate safety and tolerability in PD-LID patients. In addition, the trial was designed to evaluate exploratory efficacy as a secondary objective. Efficacy was measured using the modified Abnormal Involuntary Movement Scale (mAIMS), patient diaries documenting “off-time” (impaired voluntary movement), “on-time” (with or without dyskinesia) and sleep. Additional endpoints include the Unified Parkinson’s Disease Rating Scale (UPDRS), the Clinician & Patient Global Impression of Change (CGIC & PGIC), and an evaluation of the patients’ mood using the Hospital Anxiety & Depression Score. The trial was supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research.

About mGlu5 Inhibition

There is an increasing body of evidence that mGlu5 inhibition may be a valuable new strategy for treating a number of important diseases and conditions, such as Parkinson's disease, Parkinson’s disease levodopa-induced dyskinesia (PD-LID), dystonia, anxiety, depression, pain, tardive dyskinesia, addiction, autism and Fragile X syndrome. With regards to Parkinson’s disease, recent clinical and preclinical evidence suggest that mGlu5 inhibition may have an effect on parkinsonian motor symptoms as well as dyskinesia. mGlu5 is found in regions of the brain considered to be key control points in the neuronal movement circuits affected by abnormal signaling by the neurotransmitter glutamate in Parkinson’s disease. Perturbations in glutamate signaling (along with disruptions in dopaminergic signaling) are believed to be an underlying cause of movement disorders like Parkinson's disease and dystonia. As such, inhibiting mGlu5 could act to re-establish normal movement via a non-dopaminergic mechanism. Separately, preclinical findings also suggest that mGlu5 inhibitors may be neuroprotective and may, therefore, hold potential as disease modifying agents that can slow or prevent progression of Parkinson’s and other neurological diseases.

About Dystonia

Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily, according to the Dystonia Medical Research Foundation. The involuntary muscle contractions force the body into repetitive and often twisting movements as well as awkward, irregular postures. There are over 20 forms of dystonia, and dozens of diseases and conditions include dystonia as a major symptom. Dystonia may affect a single body area or be generalized throughout multiple muscle groups. Dystonia affects men, women, and children of all ages and backgrounds. Estimates suggest that no less than 300,000 people in North America are affected. Dystonia causes varying degrees of disability and pain, from mild to severe. There is presently no cure, and, although many drugs are utilized to try to treat dystonia, the leading treatment is botulinum toxin injections and many patients are left with inadequate efficacy. Patients also resort to invasive, risky and expensive procedures such as deep brain stimulation to treat dystonia.  Dipraglurant has been shown to effectively reduce dystonia in both a clinical study and preclinical models of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). The neurophysiology of different forms of dystonia is thought to be similar and recent preclinical data in dystonia - suggesting that dipraglurant may also work for non-parkinsonian forms of dystonia. Addex plans to initiate Phase 2 pilot studies in certain rare forms of dystonia in the first half of 2013 with the results expected towards the end of 2013.

About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a development stage company focused on advancing innovative oral small molecules against rare diseases utilizing its pioneering allosteric modulation-based drug discovery platform. The Company’s two lead products are being investigated in Phase 2 clinical testing: dipraglurant (dipraglurant, an mGlu5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. to treat both schizophrenia and anxiety as seen in patients suffering from major depressive disorder. Addex is also advancing several preclinical programs including: GABA-BR positive allosteric modulator (PAM) for Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4 PAM for MS, Parkinson’s disease, anxiety and other diseases. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to target receptors and other proteins that are recognized as essential for the therapeutic modulation of important diseases with unmet medical needs.

Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR(at)addextherapeutics.com

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management’s expectations regarding allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction


ADX71441 reversed somatic signs of withdrawal in nicotine-dependent mice and reversed hyperalgesia, further supporting the use of GABA-B activation as a strategy to achieve smoking cessation

Geneva, Switzerland, 10...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

 

Geneva, Switzerland, 30 June 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all...

Addex Therapeutics Publishes Annual General Meeting Agenda

Geneva, Switzerland, 12 June 2014 - Addex Therapeutics (SIX:...

Addex Therapeutics Publishes Annual Report 2013

 

Geneva, Switzerland, 30 May 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press release of 30 April...

Addex Therapeutics Reports 2013 Financial Results

 

2013 Financial Highlights

  • Significant reduction in 2013 cash utilization of CHF12.3 million, significantly below guidance of CHF15 million, CHF1.6 million used in second half of 2013...

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

 

Geneva, Switzerland, 7 February 2014 - (SIX:ADXN), Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today top-line data from a Phase 2a...

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

 

Geneva, Switzerland, 4 November 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the...

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

On track to report top line results end of Q1 2014

Geneva, Switzerland, 29 October 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development...

Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

Geneva, Switzerland, 3 October 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that ADX71441 dose...

Addex Therapeutics First Half 2013 Financial Results

 

Geneva, Switzerland, 17 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today its first...

Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

 

Geneva, Switzerland, 4 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today additional...

Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

Cash runway extended to end of 2014

Geneva, Switzerland, 9 August 2013 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.2 million (US$3.5 million) in a private placement...

Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

                             
Geneva, Switzerland, 31 May...

Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders


Company intends to restructure the organization and monetize its pipeline and platform assets

Geneva, Switzerland, 28 May 2013 – Addex Therapeutics (SIX: ADXN), announced today that it...

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

  • ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model
  • The data confirms the role of gamma-aminobutyric acid (GABA) in modulating GH plasma concentrations...

Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

 

• Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human primate model of Parkinson’s Disease levodopa-induced dyskinesia
• Data reinforces Phase 2a pharmacological...

Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

 

Geneva, Switzerland, 30 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief...

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence


• Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator
• Recent approval of Clinical Trial Application (CTA)  to initiate a Phase 1, first–in-man,...

Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441


ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half of 2013 and to deliver top-line safety, PK and biomarker data by year...

Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystonias

Geneva, Switzerland, 22 April 2013 – Addex Therapeutics (SIX:ADXN),...

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studies for levodopa-induced dyskinesia is on track for start of Phase 2 studies in rare dystonias in the first half of...

Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia

Geneva,...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

Geneva, Switzerland, 20 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its...

Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia

<link...

Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology...

Addex to Focus Resources on Clinical Pipeline

 

2013 Value Drivers:

• Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication
• Submit Orphan Drug Application in U.S. and Europe for dipraglurant<br...

Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia


Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013

 

Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441

ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013

Allostery: Key to addressing important unmet needs in CNS diseases

Addex'high throughput allosteric drug discovery platform is paving the way for a new approach to cracking "undruggable" therapeutic targets.

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking

- Data reinforces broad therapeutic potential of oral ADX71441 

-

Dyskinesia: Hope on the Horizon

YouTube

Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases


Grant to Further Characterize Allosteric Modulators Against mGluR4 and mGluR7
Geneva, Switzerland, 2 October 2012

Addex...

Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model

A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
Geneva, Switzerland, 24 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering...

Soutien américain au biotech à Genève

ADDEX.Le titre a bénéficié d'un regain d'intérêt des investisseurs outre-Atlantique.
La direction plaide encore la sous-évalutation.

Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms

Geneva, Switzerland, 17 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug...

Addex Therapeutics First Half 2012 Financial results

Geneva, Switzerland, 22 August 2012 – Addex Therapeutics...

Positive Early Results for Addex Parkinson's Drug Dipraglurant Spur Hopes for Deal


In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa.

Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models


- Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Modulation on Motor Symptoms 

Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder

  • Program on track for IND filing before end of 2012
  • GABA-BR PAM compounds have potential in several major Indications

Geneva,...

Addex expects data from dipraglurant trial

23 Feb 2012 MedNous - Addex Pharmaceuticals Ltd expects to report top-line data at the end of March for its lead allosteric modulator that is being

developed to treat patients with Parkinson’s disease who experience dyskinesia...

Addex changes name to Addex Therapeutics

Geneva, Switzerland, 21 March 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today...

Addex Pharmaceuticals Reports 2011 Financial Results

Financial Highlights 

  • Cash and cash equivalents of CHF36.1 million at 31 December 2011
  • Cash can fund operations through to 3Q 2013
  • Restructuring and pipeline...

New Addex CEO wants to prioritize pipeline quickly

Addex Pharmaceuticals’ new CEO Dr Bharatt Chowrira says he feels a sense of urgency to get on with decision-making at the allosteric modulation-focused Swiss company.

Refining GPCR Discovery Approaches

Emerging Platforms Afford Timelines More Comparable to Those for Soluble Targets.

Structures May Not Solve Everything

This week’s C&EN cover story is about how X-ray crystal structures of G-protein coupled receptors (GPCRs) help the hunt for new drugs. GPCRs are already a major target for drugs (if not the most popular drug target), but until...

Addex's return to basics strategy sees 2 drugs entering Phase II studies this month

BERLIN, March 14 (APM) - Swiss biotech Addex seems to have turned the corner after the failure of its lead compound during Phase II testing at the end of 2009, with two compounds entering Phase II studies within the next few...

BioCentury This Week: Katie Hood discusses funding Parkinson's disease research

BioCentury Washington Editor Steve Usdin recaps that disease groups provide urgency, a unique perspective on risk and a reminder that patients still demand drugs in an era of healthcare cost-cutting.

Addex wins EuropaBio’s European Biotech SME Award

Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”.

Therapeutic focus - Parkinson's dyskinesia treatments making progress

The cornerstone of Parkinson’s disease treatment, levodopa, is an effective yet tainted drug - eventually causing side effects as debilitating as the disease it treats.

Glutamate Modulation as Parkinson’s Therapy

Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes.

Dissipating a slow torture

While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea...